Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-12-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients with Hematologic Malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease

NCT00504803

Hematological Malignancies

COMPLETED PHASE2

Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia

NCT00797758

Acute Myeloid Leukemia

COMPLETED PHASE2

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

NCT06294691

Acute Graft-versus-host Disease

RECRUITING PHASE3

Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients

NCT02623309

Hematologic Neoplasms

COMPLETED PHASE3

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies

NCT06294678

Acute Graft-versus-host Disease

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary end points are treatment-related mortality and engraftment. Secondary end points are regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HEMATOLOGIC MALIGNANCIES

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Patients should have an unrelated donor who is matched for HLA-A and -B by serology and for -DRB1 by molecular typing.

Exclusion Criteria

* Patients should not have major illness or organ failure
* Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.
* Patients must not be pregnant or lactating.

Minimum Eligible Age

15 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No